NY-ESO-1 expression in DCIS: A new predictor of good prognosis.

ABSTRACT:

Background

At present, it is difficult to predict which patients with ductal carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer (IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both expressed in DCIS. This study was aimed at determining whether expression of these antigens was related to the later development of IDC.

Results

14 of 42 (33%) of patients developed invasive breast cancer during the follow up period. Only one of those DCIS cases that relapsed was positive for NYESO-1 at diagnosis. In contrast, DCIS samples of 15 of the 28 (54%) of those patients who remained disease-free expressed NY-ESO-1. (Permutation chi square p=0.0033).

Methods

We identified 42 patients with DCIS, and followed them up for more than

SUBMITTER: Coombes RC 

PROVIDER: S-EPMC5441475 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature